- Case report
- Open Access
Clinical course of choroidal neovascular membrane in West Nile virus chorioretinitis: a case report
Journal of Medical Case Reports volume 15, Article number: 206 (2021)
This report describes the clinical course of choroidal neovascular membrane (CNV) in West Nile virus-associated chorioretinitis.
A 28-year-old Italian woman was referred to our institution because of reduced visual acuity in the left eye dating back 4 months. A diagnosis of retinal vasculitis in the right eye and chorioretinitis with CNV in the left eye was made. A complete workup for uveitis revealed positivity only for anti-West Nile virus immunoglobulin M (IgM), while immunoglobulin G (IgG) was negative. Whole-body computed tomography and nuclear magnetic resonance imaging of the brain were also negative. Therefore, the patient was treated with a combination of oral prednisone (starting dose 1 mg/kg per day) and three intravitreal injections of bevacizumab 1.25 mg/0.05 ml, 1 month apart. Fourteen days from starting corticosteroid therapy and after the first intravitreal injection, the patient experienced increased visual acuity to 0.4. Response to therapy was monitored by clinical examination, ocular coherence tomography (OCT), OCT angiography and retinal fluorescein angiography. Three months later, resolution of CNV in the left eye was achieved and no signs of retinal vasculitis were detected in the right eye, while serum IgM for West Nile virus turned negative and IgG positive.
CNV may be a complication of West Nile virus-associated chorioretinitis, and only subclinical retinal vasculitis may also be found even in non-endemic regions.
West Nile virus (WNV) is a single-stranded ribonucleic acid (RNA) virus that belongs to the family Flaviviridae. It causes a zoonosis transmitted from birds to humans through mosquitos. This infectious disease has spread rapidly in America since 2015, but it has also been reported as endemic in Europe, Asia and Africa. WNV infection is quite rare in Italy.
Clinical manifestations of WNV infection can occur as an asymptomatic form (nearly 80% of cases), as West Nile fever (20% of subjects) and as West Nile meningoencephalitis in less than 1%. This last clinical manifestation is mainly related to immunosuppression or diabetes. The WNV incubation period is 3 to 14 days, after which fever, headache, diffuse myalgia, asthenia, gastrointestinal symptoms and maculopapular rash may occur. Neurological involvement includes meningitis, encephalitis and meningoencephalitis . Treatment consists of intravenous injection of alpha interferon, ribavirin and immunoglobulins, which have been proposed only for the most severe forms.
Several ocular manifestations of WNV infection, including occlusive ischemic stroke, optic neuritis, sixth cranial nerve palsy, nystagmus, multifocal chorioretinitis, chorioretinal scarring and uveitis without focal lesions, have been described. The most common manifestation is chorioretinitis characterized by the presence of 100–1500-micron circular lesions with cream-colored margins in the active form or well-defined chorioretinal scars after resolution. Sometimes a mild to moderate vitreous haze can be found in the active form .
Fluorescein angiography (FAG) and indocyanine green angiography (ICGA) are essential ancillary tools used in WNV-associated ocular involvement. Active lesions, which are deep and cream-colored on fundus examination, during the early phase of FAG are round-shaped hyperfluorescent dots with subsequent late staining. Inactive lesions are atrophic and partially pigmented, centrally hypofluorescent with some hyperfluorescence at the margins. At ICGA, lesions appear hypocyanescent. Ocular coherence tomography (OCT) scan shows deep lesions not involving the internal retinal layers and the nerve fiber layer .
Diagnosis of WNV-associated ocular lesions is based on clinical examination, detection of specific immunoglobulin M (IgM) antibodies and exclusion of other more common forms of uveitis . Excluding the most severe cases, for which hospitalization is needed, West Nile chorioretinitis is considered to be a self-limiting pathology with a partial recovery of visual function if secondary inflammatory choroidal neovascularization (CNV) does not occur .
The aim of this case report is to describe, in the first case of WNV-associated chorioretinitis diagnosed in Italy, the clinical course of the disease and its complications.
A 28-year-old Italian woman was referred to our institution because of reduced visual acuity in the left eye dating back 4 months.
Medical history was unremarkable from 4–5 months prior to our observation, when the patient developed persistent fever (37.5°C) for about 1 month, occasionally accompanied by urticaria-like reactions on her trunk and limbs, diagnosed as contact dermatitis (Fig. 1).
At that time the patient was living in the northern part of Italy, working at a company producing poultry feed and soil fertilizers. Two weeks after the onset of systemic lesions, she developed a sudden drop in visual acuity in her left eye. She was diagnosed elsewhere with myopia-related CNV and was treated with two intravitreal injections of ranibizumab 0.5 mg, 1 month apart, without any improvement.
During our first examination, she presented with mild myopia (−1.5 diopters) and best-corrected visual acuity (BCVA) of 0.2 in the left eye, normal anterior segment, no cataract, and a partially pigmented yellowish ameboid lesion in the macular region. Small, round, cream-colored spots were observed in the perimacular region (Fig. 2a). BCVA in the right eye was 1 (−2 diopters). Anterior and posterior segments were both normal. Intraocular pressure was 14 mmHg in both eyes.
Multimodal imaging was carried out and demonstrated active retinal vasculitis in the right eye (Figs. 2c, 3a) (undetectable on ophthalmoscopy) and active CNV in combination with multiple chorioretinal scars in the left eye (Figs. 2a, b, 3b).
The clinical history of the patient, the signs of retinal vasculitis in the contralateral eye and the mild myopia suggested an investigation of possible infectious retinal disease as differential diagnosis.
Therefore, we performed a complete workup for uveitis including Mantoux skin test and QuantiFERON-TB Gold test, Venereal Disease Research Laboratory (VDRL) and Treponema pallidum particle agglutination (TPHA) tests, anti-Toxoplasma and anti-Toxocara antibodies, antiviral antibodies (Herpes simplex virus type-1 [HSV1], Herpes simplex virus type-2 [HSV2], Epstein-Barr virus [EBV], Cytomegalovirus [CMV], Varicella-zoster virus [VZV]), anti-Brucella, anti-Bartonella and anti-Rickettsia antibodies and blood cell count, along with erythrocyte sedimentation rate, C-reactive protein, and liver and kidney evaluation tests. Furthermore, considering the latest news reporting some cases of West Nile in the northern part of Italy, where the patient had spent some months, we also investigated for West Nile IgM and IgG antibodies. The laboratory results showed an increase in lymphocytes, erythrocyte sedimentation rate and C-reactive protein, and positivity for anti-West Nile virus IgM, while IgG was negative.
Hence, the patient was sent to an infectious diseases specialist and underwent a whole-body computed tomography scan and nuclear magnetic resonance imaging of the brain, which both yielded normal results. Therefore, a minor self-limiting West Nile infection with ocular involvement complicated by CNV was diagnosed.
The patient was treated with a combination of oral corticosteroids (starting dose: 1 mg/kg per day of prednisone, slowly tapered and stopped in 12 weeks) and three intravitreal injections of bevacizumab 1.25 mg/0.05 ml, 1 month apart, because ranibizumab is not approved in Italy for post-inflammatory choroidal neovascularization. Fourteen days from starting corticosteroid therapy and after the first intravitreal injection, the patient experienced an increase in BCVA to 0.4.
Follow-up and outcomes
Response to therapy was monitored by clinical examination, OCT, OCT angiography and retinal FAG. ICGA was not repeated because of fainting occurring during the first exam. Clinical findings 3 months after starting therapy are shown in Fig. 4: resolution of CNV was achieved, with no intraretinal fluid in the left eye, while no vasculitis was detected in the right eye; serum IgM for WNV turned negative and IgG positive.
After stopping therapy, the patient was followed up for an additional 14 months, with no evidence of recurrence of active inflammation or choroidal neovascularization. Final BCVA was 0.5 in the left eye and 1 in the right eye.
WNV infection is an emerging disease worldwide, and ocular involvement may occur as an asymptomatic form or as lesions with significant morbidity .
Systemic therapy for WNV infection is usually suggested by infectious disease specialists to treat and control only the most severe cases, namely those with neurologic involvement. Nevertheless, our case demonstrated that systemic therapy with corticosteroids may be beneficial for the treatment of subclinical retinal lesions, such as retinal vasculitis. There were no retinal lesions in the eye presenting with retinal vasculitis. This can be found only with FAG and might occur even independently from the presence of chorioretinal lesions or scars. In such a case, systemic antiviral therapy was not needed, because systemic active lesions were absent.
Chorioretinal lesions are the most frequent inflammatory ocular findings, but they do not present any peculiar features. Choroidal neovascularization may occur as a complication in patients with chorioretinal lesions of different etiologies, with elapsed time from the acute disease ranging from weeks to years .
In those cases, intravitreal injections of anti-vascular endothelial growth factor (VEGF) are a reasonable approach, leading to resolution of the lesions usually with only a few intravitreal injections.
No significant difference in terms of ocular recovery has been demonstrated among different anti-VEGF drugs. In our patient, diagnosis of WNV infection was made based on the patient’s history of positivity to the specific serologic tests. Nevertheless, any test useful for excluding other more common entities was done and resulted in negative findings. CNV was the first symptomatic lesion recalled by the patient, and it failed to achieve any significant results with two injections of ranibizumab. Therefore, considering the presence of active vasculitis in the contralateral eye and the active CNV, we decided to treat the patient with three further injections of bevacizumab, given in combination with systemic corticosteroid therapy. This therapeutic regimen enabled complete resolution of the neovascularization and retinal vasculitis (Fig. 4a), with a relapse-free period of 14 months after therapy withdrawal. It is possible that a higher number of injections and, probably, the combined treatment with systemic corticosteroid and anti-VEGF intravitreal injections, as suggested by other authors, led to the resolution of CNV in our patient. OCT and OCT angiography were essential tools in the follow-up of the complications found in our case (Fig. 5): they are noninvasive, and in a patient with suspected intolerance to ICGA, they were able to adequately follow the clinical course of both CNV and chorioretinal lesions. Nevertheless, as previously suggested, they should be performed, if possible, in combination with FAG and ICGA, which are able to detect subclinical inflammation in retinal vessels and in the choroid. In conclusion, WNV ocular infection is another ocular inflammatory disease in which a multimodal imaging approach is essential for adequate diagnosis and follow-up of the disease course and its response to treatment.
Our case highlights the possibility that even in a non-endemic country, WNV may occur, along with its ocular manifestations, namely CNV. Not all ocular lesions are symptomatic: vasculitis may occur in a chorioretinal lesion-free eye, and even the presence of chorioretinitis may be asymptomatic . Nevertheless, chorioretinal asymptomatic lesions may become symptomatic after the development of chorioretinal neovascularization. A viral infection can also lead to unilateral involvement, for example, in CMV infection and in patients suffering from herpes-related acute retinal necrosis.
Patient perspective: In such a case, combined therapy with systemic corticosteroids and anti-VEGF may control all the ocular manifestations, without recurrence over medium-term follow-up.
Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Best-corrected visual acuity
Choroidal neovascular membrane
Indocyanine green angiography
Ocular coherence tomography
West Nile virus
Vascular endothelial growth factor
Yahia SB, Khairallah M. Ocular manifestations of West Nile virus infection. Int J Med Sci. 2009;6:114–5.
Chan CK, Limstrom SA, Tarasewicz DG, Lin SG. Ocular features of West Nile virus infection in North America: a study of 14 eyes. Ophthalmology. 2006;113:1539–46.
Learned D, Nudleman E, Robinson J, Chang E, Stec L, Faia LJ, et al. Multimodal imaging of west Nile virus chorioretinitis. Retina Phila Pa. 2014;34:2269–74.
Khairallah M, Kahloun R, Ben Yahia S, Jelliti B, Messaoud R. New infectious etiologies for posterior uveitis. Ophthalmic Res. 2013;49:66–72.
Seth RK, Stoessel KM, Adelman RA. Choroidal neovascularization associated with West Nile virus chorioretinitis. Semin Ophthalmol. 2007;22:81–4.
Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, et al. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 2013;156(468–477):e2.
Gohari AR, Willson RL, Gitter KA. West Nile virus occlusive retinal vasculitis. Retin Cases Brief Rep. 2011;5:209–12.
This case report did not have any funding to disclose.
Ethics approval and consent to participate
This is a case report. Consent to publish was obtained from the patient.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors have no conflicts of interest to declare
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zito, R., Micelli Ferrari, T., Di Pilato, L. et al. Clinical course of choroidal neovascular membrane in West Nile virus chorioretinitis: a case report. J Med Case Reports 15, 206 (2021). https://doi.org/10.1186/s13256-021-02700-0
- Retinal vasculitis